Navigation Links
Researchers discover brain cancer treatment using genetic material from bone marrow cells
Date:4/1/2013

DETROIT In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel approach for treatment of tumor. Specifically, the research team found that introducing genetic material produced by MSCs, significantly reduced a particularly resistant form of malignant brain tumor in living lab rats.

"This is the first foray of its type in experimental cancer therapy, and it represents a highly novel and potentially effective treatment," says Michael Chopp, Ph.D., scientific director of the Henry Ford Neuroscience Institute and vice chairman of the Department of Neurology at Henry Ford Hospital. The research is published in the current issue Cancer Letters.

"I think this is an important and very novel approach for the treatment of cancers, and in this particular case the treatment of glioma," says Dr. Chopp. "We have been at the forefront of developing microRNAs as a means to treat disease, such as cancer and neurological injury.

"This study shows it is effective in the living brain, and may even lend itself to specific cancer therapy, customized for the individual patient," Chopp adds

Chopp and his colleagues focused their efforts on glioma, by far the most common type of malignant brain tumor, and one with a notably poor prognosis for survival.

Tumor cells were surgically implanted in the brains of anesthetized male lab rats and allowed to grow for five days. The tumors then were injected with exosomes containing molecules of a microRNA called miR-146b found in earlier Henry Ford research to have a strong effect on glioma cells.

Exosomes are microscopic "lipid bubbles" that once were thought to carry and get rid of "old" proteins that were no longer needed by the body. After they were more recently found to also carry RNA, whole new fields of study were suggested including groundbreaking work by Henry Ford researchers.

In their rat study, Chopp and his colleagues used MSC bone marrow cells to produce the exosomes containing the miR-146b they injected into the cancerous tumors.

Five days after this treatment, the rats were euthanized and their brains were removed, prepared for study, and examined. Tumor size was measured using computer software.

"We found that one injection of exosomes containing miR-146b five days after tumor implantation led to a significant reduction in tumor volume at 10 days after implant," Chopp says. "Our data suggest that miR-146b elicits an anti-tumor effect in the rat brain, and that MSCs can be used as a "factory" to generate exosomes genetically altered to contain miR-146b to effectively treat tumor. "


'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-876-8709
Henry Ford Health System
Source:Eurekalert

Related biology news :

1. Notre Dame researchers are using new technologies to combat invasive species
2. University of Montreal researchers discover how drug prevents aging and cancer progression
3. Researchers question evaluation methods for protected areas in the Amazon
4. Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device
5. Researchers find novel mechanism regulating replication of insulin-producing beta cells
6. Researchers find novel way plants pass traits to next generation
7. Ludwig cancer researchers honored among first class of fellows in AACR Academy
8. Researchers issue forecast for moderate New England red tide in 2013
9. Researchers spot molecular control switch for preterm lung disorders
10. Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug
11. Dartmouth researchers invent real time secondhand smoke sensor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , the ... of its patent portfolio, which grew to over 40 granted and pending ... , , ... filed patent entitled " System, Device, and Method Estimating Force ... enables device makers to forego costly hardware components needed to estimate the ...
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... San Jose, CA (PRWEB) , ... January 17, 2017 , ... ... people cultivate a balanced, peaceful and healthy lifestyle, announced today the official launch of ... body and frees the mind. , In development for over a year, ...
(Date:1/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... initiated a global Phase 2b induction study in ... targets alpha4beta7 integrin. The aim of this randomized, ... the safety/tolerability and efficacy of PTG-100 in approximately ... severe active disease. "We are ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... prestigious Tibbetts Award from the U.S. Small Business Administration. The Tibbetts ... significant economic or social impact […] and are considered the best of the ...
(Date:1/13/2017)... 13, 2017 Research and Markets has announced ... - Global Forecast to 2021" report to their offering. ... The biosimilars market ... 3.39 Billion in 2016, at a CAGR of 26.3%. ... product, manufacturing type, and application. Factors such as rising incidence of ...
Breaking Biology Technology: